Myriad Genetics, Inc.‘s (MYGN) share price has entered into oversold territory with a stochastic value of 17.588. The Zacks Consensus Estimate on the company’s earnings for June 2012 increased by 2 cents over the past month to $1.26 per share. Myriad Genetics is a Zacks #2 Rank (“Buy”) company.
To read this article on Zacks.com click here.
Zacks Investment Research
